ImageneBio Inc (IMA)
ImageneBio Inc at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
ImageneBio Inc (IMA) is a Biotechnology company based in US with a market capitalization of $67.7M. Revenue declined 77.1% year-over-year and free cash flow was negative at -$47.8M. This page tracks IMA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 10 employees · IPO Feb 27, 1998
Valuation
Valuation & price
$5.68as of May 17, 2026· -68.3% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.51
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$67.7M
Market cap
-77.1%
Revenue growth (YoY)
-29.1%
Gross margin
-$47.8M
Free cash flow (USD)
-$65.8M
Net debt
Net cash position
-89.9%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2018 → 2025
Free cash flow by year
2018 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
1
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 23, 2026Filing
Severance Plan Established
- Insider sellJul 20, 2026Filing
Insider Sell $17KLally Robert B · Principal Accounting Officer · $17.3K
- 8-K eventJun 26, 2026Filing
Executive Resignation
- 8-K eventJun 17, 2026Filing
Equity Incentive Plan Amended
- 8-K eventMay 7, 2026Filing
Earnings Release
- Quarterly reportMay 7, 2026Filing
10-Q Filed
- 8-K eventApr 13, 2026Filing
Securities Purchase Agreement
Questions
Frequently asked questions
What is ImageneBio Inc's market cap?
ImageneBio Inc (IMA) has a market capitalization of $67.7M.
What is IMA's P/E ratio?
A meaningful P/E ratio is not available for IMA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is IMA's price-to-book (P/B) ratio?
IMA trades at 0.51 times book value per share.
Are insiders buying IMA stock?
SEC Form 4 filings show no open-market insider buys at ImageneBio Inc in the last 90 days (1 sell).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.